Skip to main content Accessibility help


  • Access
  • Cited by 19
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Hawkins, Nicole A. Anderson, Lyndsey L. Gertler, Tracy S. Laux, Linda George, Alfred L. and Kearney, Jennifer A. 2017. Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. Annals of Clinical and Translational Neurology, Vol. 4, Issue. 5, p. 326.

    Wirrell, Elaine C. Laux, Linda Donner, Elizabeth Jette, Nathalie Knupp, Kelly Meskis, Mary Anne Miller, Ian Sullivan, Joseph Welborn, Michelle and Berg, Anne T. 2017. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatric Neurology, Vol. 68, Issue. , p. 18.

    Valeta, Thalia 2017. The Epilepsy Book: A Companion for Patients. p. 63.

    Mei, Davide Parrini, Elena Marini, Carla and Guerrini, Renzo 2017. The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients. Molecular Diagnosis & Therapy, Vol. 21, Issue. 4, p. 357.

    Schoonjans, An-Sofie Marchau, Fabienne Paelinck, Bernard P. Lagae, Lieven Gammaitoni, Arnold Pringsheim, Milka Keane, Martin G. and Ceulemans, Berten 2017. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Current Medical Research and Opinion, Vol. 33, Issue. 10, p. 1773.

    Villas, Nicole Meskis, Mary Anne and Goodliffe, Sue 2017. Dravet syndrome: Characteristics, comorbidities, and caregiver concerns. Epilepsy & Behavior, Vol. 74, Issue. , p. 81.

    O'Connell, Brooke K. Gloss, David and Devinsky, Orrin 2017. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy & Behavior, Vol. 70, Issue. , p. 341.

    Shellhaas, Renée A. Berg, Anne T. Grinspan, Zachary M. Wusthoff, Courtney J. Millichap, John J. Loddenkemper, Tobias Coryell, Jason Saneto, Russell P. Chu, Catherine J. Joshi, Sucheta M. Sullivan, Joseph E. Knupp, Kelly G. Kossoff, Eric H. Keator, Cynthia Wirrell, Elaine C. Mytinger, John R. Valencia, Ignacio Massey, Shavonne and Gaillard, William D. 2017. Initial Treatment for Nonsyndromic Early-Life Epilepsy: An Unexpected Consensus. Pediatric Neurology, Vol. 75, Issue. , p. 73.

    Sugiura, Yoshihiro and Ugawa, Yoshikazu 2017. Epilepsy and ion channels. Rinsho Shinkeigaku, Vol. 57, Issue. 1, p. 1.

    Maljevic, Snezana Reid, Christopher A. and Petrou, Steven 2017. Models for discovery of targeted therapy in genetic epileptic encephalopathies. Journal of Neurochemistry, Vol. 143, Issue. 1, p. 30.

    James Huntsman, Richard Tang-Wai, Richard Acton, Bryan Alcorn, Jane William Lyon, Andrew David Mousseau, Darrell Seifert, Blair Laprairie, Robert Prosser-Loose, Erin and Ondrej Hanuš, Lumir 2018. Cannabis for the treatment of paediatric epilepsy? An update for Canadian paediatricians. Paediatrics & Child Health, Vol. 23, Issue. 6, p. 368.

    Yan, Ni Xin-Hua, Wang Lin-Mei, Zhang Yi-Ming, Chai Wen-Hui, Li Yuan-Feng, Zhou and Shui-Zhen, Zhou 2018. Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome. Seizure, Vol. 60, Issue. , p. 144.

    Wykes, R.C. and Lignani, G. 2018. Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology, Vol. 132, Issue. , p. 108.

    Devinsky, Orrin Nabbout, Rima Miller, Ian Laux, Linda Zolnowska, Marta Wright, Stephen and Roberts, Claire 2018. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia,

    Zaman, Tariq Helbig, Ingo Božović, Ivana Babić DeBrosse, Suzanne D. Bergqvist, A. Christina Wallis, Kimberly Medne, Livija Maver, Aleš Peterlin, Borut Helbig, Katherine L. Zhang, Xiaohong and Goldberg, Ethan M. 2018. Mutations in SCN3A cause early infantile epileptic encephalopathy. Annals of Neurology, Vol. 83, Issue. 4, p. 703.

    Sanders, Stephan J. Campbell, Arthur J. Cottrell, Jeffrey R. Moller, Rikke S. Wagner, Florence F. Auldridge, Angie L. Bernier, Raphael A. Catterall, William A. Chung, Wendy K. Empfield, James R. George, Alfred L. Hipp, Joerg F. Khwaja, Omar Kiskinis, Evangelos Lal, Dennis Malhotra, Dheeraj Millichap, John J. Otis, Thomas S. Petrou, Steven Pitt, Geoffrey Schust, Leah F. Taylor, Cora M. Tjernagel, Jennifer Spiro, John E. and Bender, Kevin J. 2018. Progress in Understanding and Treating SCN2A -Mediated Disorders. Trends in Neurosciences, Vol. 41, Issue. 7, p. 442.

    Orsini, Alessandro Zara, Federico and Striano, Pasquale 2018. Recent advances in epilepsy genetics. Neuroscience Letters, Vol. 667, Issue. , p. 4.

    Lagae, Lieven Brambilla, Isabella Mingorance, Ana Gibson, Eddie and Battersby, Alysia 2018. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Developmental Medicine & Child Neurology, Vol. 60, Issue. 1, p. 63.

    Ziobro, Julie Eschbach, Krista Sullivan, Joseph E. and Knupp, Kelly G. 2018. Current Treatment Strategies and Future Treatment Options for Dravet Syndrome. Current Treatment Options in Neurology, Vol. 20, Issue. 12,



      • Send article to Kindle

        To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Treatment of Dravet Syndrome
        Available formats

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Treatment of Dravet Syndrome
        Available formats

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Treatment of Dravet Syndrome
        Available formats
Export citation


Dravet syndrome is among the most challenging electroclinical syndromes. There is a high likelihood of recurrent status epilepticus; seizures are medically refractory; and patients have multiple co-morbidities, including intellectual disability, behaviour and sleep problems, and crouch gait. Additionally, they are at significant risk of sudden unexplained death. This review will focus predominantly on the prophylactic medical management of seizures, addressing both first-line therapies (valproate and clobazam) as well as second-line (stiripentol, topiramate, ketogenic diet) or later options (levetiracetam, bromides, vagus nerve stimulation). Sodium channel agents—including carbamazepine, oxcarbazepine, phenytoin and lamotrigine—should be avoided, as they typically exacerbate seizures. Several agents in development may show promise, specifically fenfluramine and cannabidiol, but they need further evaluation in randomized, controlled trials. In addition to prophylactic treatment, all patients need home-rescue medication and a status epilepticus protocol that can be carried out in their local hospital. Families must be counselled on non-pharmacologic strategies to reduce seizure risk, including avoidance of triggers that commonly induce seizures (including hyperthermia, flashing lights and patterns). In addition to addressing seizures, holistic care for a patient with Dravet syndrome must involve a multidisciplinary team that includes specialists in physical, occupational and speech therapy, neuropsychology, social work and physical medicine.

Dravet syndrome (DS) is an intractable paediatric electroclinical syndrome beginning in the first 24 months of life, with generalized or hemi-convulsive seizures initiated by fever (often associated with vaccines) or hyperthermia, which are often prolonged. In early childhood, between 1 and 5 years of age, other seizure types emerge, including myoclonic, atypical absence and focal seizures, as well as periods of obtundation (non-convulsive) status epilepticus. This review will outline treatment goals and the first-, second-line and later therapies for seizures (pharmacologic and non-pharmacologic) and agents in development, as well as address management of status epilepticus.

Treatment Goals

In managing patients with DS, the aim is to significantly reduce seizure frequency (particularly prolonged events) and limit antiepileptic drug toxicity. Complete seizure cessation is rarely achievable. Another therapeutic goal is to minimize co-morbidities, including intellectual disability, behavioural and psychiatric problems, seizure-related injury and sudden unexplained death in epilepsy (SUDEP). A greater degree of cognitive and behavioural impairment has been linked to both higher frequency of convulsive 1 and non-convulsive seizures. 2 , 3

The typical seizure pattern changes over time. Status epilepticus is most problematic during the first two years of life and reduces in frequency after five years of age. In early childhood, frequent non-convulsive seizures may negatively impact development. In the adolescent and adult years, frequent but brief nocturnal generalized convulsive seizures are most common and place the patient at risk of SUDEP.

Provocation of seizures by hyperthermia, and less frequently by photosensitivity or pattern sensitivity, is commonly noted. Antipyretics for fever, minimizing warm baths or exercise on warm days, and avoiding photosensitivity triggers are recommended.

Prophylactic Seizure Management (see Table 1)

Treatment of DS should begin when this diagnosis is suspected, rather than waiting for genetic confirmation. Importantly, certain antiepileptic agents should be avoided, as they have been clearly shown to exacerbate seizures in DS. These include carbamazepine, 4 oxcarbazepine, phenytoin, lamotrigine, 5 vigabatrin, 4 phenobarbital 6 , 7 and rufinamide. 8

Table 1 Second-line medications in Dravet Syndrome

STP=stiripentol; VPA=valproate; CLB=clobazam; TPM=topiramate; LEV=levetiracetam; ZNS=zonisamide; CI=confidence interval; GTCS=generalized tonic-clonic seizure.

* Based on Oxford Centre for Evidence-Based Medicine, 2011. 13

There have been few evidence-based studies to evaluate the best therapies for DS, and recommendations for most first- and second-line therapies are based predominantly on expert opinion and a limited number of small, mostly retrospective, open-label studies. Only one agent, stiripentol, has published evidence of level 2 efficacy, based on placebo-controlled, randomized, double-blind studies. 9 However, preliminary data from a randomized, placebo-controlled, double-blind study on cannabidiol also provide level 2 evidence of efficacy (, although these data are not yet published. Open-label prospective studies have also been performed using topiramate 10 , 11 and levetiracetam. 12 The Oxford Center for Evidence-Based Medicine has defined five levels of evidence to determine therapeutic benefit, ranging from the highest (level 1: evidence of efficacy based on a systemic review of randomized trials) to the lowest (level 5: evidence of efficacy based on mechanism-based reasoning only). 13 For each therapeutic intervention, the level of evidence to support its use in DS will be provided.

First-Line Management: Valproic acid and Clobazam

First-line management typically involves either valproic acid or clobazam. Valproic acid is a broad-spectrum agent with multiple possible mechanisms of action, including potentiation of GABAergic function, inhibition of voltage-sensitive sodium channels and antagonism of NMDA receptor-mediated neural excitation. There is minimal literature on its use in DS (level 4), and in retrospective studies 14 , 15 responder rates (>50% reduction in seizure frequency) were 22.2-48%.

Valproic acid has the potential for several severe adverse effects, including hepatotoxicity (particularly with underlying mitochondrial disease), hyperammonemia, pancreatitis and thrombocytopenia. Additionally, other adverse effects may include decreased or increased appetite, tremor (at higher doses), hair loss and sedation. It is typically started at a dose of 10-15 mg/kg/d divided bid to tid, and increased to a target dose of 25-60 mg/kg/d, depending on achieved blood levels. Monitoring of platelet count and liver function is typically recommended, particularly in younger children.

Clobazam is a benzodiazepine that is felt to have a lower potential for sedation and acts on the GABAA receptor, a pentameric structure with five subunits (2α, 2β, and one γ, δ, ε, θ or π) around a central pore, through which chloride ions pass, resulting in cellular hyperpolarization. Clobazam acts on the γ-containing GABAA receptors, which are most prevalent, predominantly responsible for fast phasic inhibition and located within the synapse. Clobazam is typically started at doses of 0.2-0.3 mg/kg/d, with target doses of 0.5-2.0 mg/kg/d commonly reached in DS. The main adverse effects of clobazam include behavioural disinhibition, sedation, ataxia and increased salivation. Again, there is a limited amount of data on the efficacy of clobazam in DS (level 4), with a single retrospective study 14 documenting responder rates of 28%.

Typically, if one first-line agent provides suboptimal control, the other is added on. However, the majority of children will require addition of a second-line agent.

Second-Line Therapies

At present, most epileptologists consider stiripentol, topiramate or the ketogenic diet as the best second-line options for patients who continue to experience poor seizure control despite valproic acid and clobazam.


Stiripentol is a positive allosteric modulator of the GABAA receptor, acting on both the benzodiazepine-sensitive γ-containing GABAA receptors as well as on the benzodiazepine-insensitive δ-containing GABAA receptors, which are predominantly peri- and extrasynaptic in location and responsible for mediating tonic inhibition. 16 Thus, the combination of stiripentol and benzodiazepines enhances GABAergic neurotransmission beyond the effect of each compound administered alone. Furthermore, in status epilepticus, stiripentol continues to be efficacious, both by maintaining phasic inhibition, due to its action on α4-containing GABAA receptors (which are not internalized), and tonic inhibition, by its action on δ-containing GABAA receptors. In contrast, pharmacoresistance develops to benzodiazepines due to internalization of the GABAA receptors containing the γ2 subunit. 17 Stiripentol has also been shown to have particular affinity for the α3 subunit-containing GABAA receptors, which are found at the highest levels in the immature brain. 18

Stiripentol is approved by Health Canada as adjunctive therapy for refractory generalized tonic-clonic seizures in DS not adequately controlled with valproic acid and clobazam. It is the only agent that has been studied in a randomized, placebo-controlled, blinded manner (level 2). 9 , 19 In the pivotal STICLO studies, 19 children receiving stiripentol added on to clobazam and valproate achieved a 69% reduction in seizure frequency from baseline, compared to a 7% increase in those treated with placebo. Overall, the odds ratio of responding to stiripentol compared to placebo was 32 (CI 95%=6.2, 161). Other retrospective analyses 4 , 14 , 15 , 20 , 21 have confirmed efficacy, with 57-89% having a >50% reduction in seizure frequency, 9-17% seizure-freedom, and significant reductions in seizure duration, frequency of status epilepticus, frequency of rescue medication use and ER visits.

Stiripentol inhibits CYP2C19, and thus, when used as a co-therapy with clobazam, results in approximately a twofold increase in clobazam levels and a three- to fivefold increase in norclobazam levels. However, subsequent studies 22 have suggested that the efficacy of stiripentol is independent of its pharmacokinetic interaction with clobazam.

Stiripentol should be combined with valproic acid and/or clobazam, as there are no clinical data to support its use as monotherapy. It is typically started at a dose of 10-15 mg/kg/d and titrated up to an initial target dose of approximately 50 mg/kg/d over 2-4 weeks. The dose can be further increased as needed to a maximum of 100 mg/kg/d in young children, although adolescents and adults require a lower dose (20-30 mg/kg/d). Because of the pharmacokinetic interaction, clobazam doses must be reduced, typically to approximately 0.2 mg/kg/d. The side effects of stiripentol are typically dose-dependent and include somnolence, fatigue, ataxia and decreased appetite. 13 It is recommended that a complete blood count and liver enzymes be monitored at baseline and then every six months while on therapy.


Topiramate is a widely available broad-spectrum antiepileptic agent that acts through multiple mechanisms, including blockage of voltage-dependent sodium channels, carbonic anhydrase inhibition, AMPA/kainite receptor antagonism and enhancing GABAA activity.

Four modest-sized, observational, open-label, prospective and retrospective studies 10 , 11 , 14 , 23 assessing the efficacy of topiramate in patients with DS (levels 3 and 4) have shown responder rates of 35-78%, with 10-17% of patients becoming seizure-free at least in the short term.

Doses used in DS are similar to other epilepsy types, starting at 0.5-2 mg/kg/d and increasing to a target of 8-12 mg/kg/d. Adverse effects include somnolence, decreased appetite, slowing of verbal processing, metabolic acidosis and nephrolithiasis. While topiramate may reduce sweating, thus predisposing to hyperthermia, which is a known seizure trigger in DS, this concern is more theoretical than practical in DS.

Ketogenic Diet (Table 2)

The ketogenic diet is a well-recognized therapy for medically intractable epilepsy, and several open-label retrospective studies (level 4) 14 , 28 - 31 have documented efficacy in DS. Overall, approximately two-thirds of patients are responders, with a minority achieving either freedom from seizure or a marked seizure reduction. In younger children, most centers utilize a traditional ketogenic diet, although the modified Atkins or low-glycemic index options may be more palatable and better tolerated in older children and teens. This diet requires strict adherence and careful supervision by a dietician. Side effects include nausea, vomiting, constipation, nephrolithiasis and hyperlipidemia.

Table 2 Ketogenic diet in Dravet Syndrome

AED=antiepileptic drug; KD=ketogenic diet.

Later Therapeutic Options

Although the data are limited, levetiracetam, bromides or vagal nerve stimulation appear less efficacious than stiripentol, topiramate or the ketogenic diet and should be considered only after failure of these second-line agents.


Levetiracetam, another broad-spectrum antiepileptic medication, whose exact mechanism of action is unknown but which binds to the synaptic vesicle protein SV2A, was reported to have a responder rate of 64% in a single open-label prospective study of 28 patients (level 3). 24 However, other retrospective studies 14 show significantly lower efficacy—closer to 11%.

It is generally a well-tolerated medication, and its major adverse effect is behavioural disinhibition. Dosing is typically started at 10-20 mg/kg/d divided bid to tid, and the dose may be increased to a maximum of 60-80 mg/kg/d. Routine blood monitoring is not required.

Vagus Nerve Stimulation (Table 3)

Several relatively small retrospective case series of vagal nerve stimulation in DS are reported, again providing level 4 evidence of efficacy. 28 , 32 - 37 Responder rates are approximately 25-35% overall, which is lower than what is typically obtained with the ketogenic diet, but they vary significantly between studies.

Table 3 Vagus nerve stimulation in Dravet syndrome

AED=antiepileptic drug; SD=standard deviation.


Bromides were initially used in the 19th century for epilepsy and are currently utilized mostly in veterinary practice. They are not available by prescription in North America. Bromides are given in the form of bromide salts, including potassium bromide, sodium bromide and ammonium bromide.

The exact mechanism of action is not known, but it is presumed that bromides act on the chloride channel of the GABAA receptor, causing hyperpolarization. Bromides have shown level 4 efficacy in DS in retrospective studies, 15 , 25 - 27 with responder rates of 37-77% and seizure-free rates of 9%, although there is a suggestion that response rates taper off over time. Oguni and colleagues 27 suggested that bromides were most effective for generalized tonic-clonic seizures and less effective for focal, absence or myoclonic seizures. The side effects of bromides are typically minor and include rash, somnolence and decreased appetite.

Agents in Development


Fenfluramine, an agent that releases serotonin by disrupting vesicular storage and reversing serotonin transporter function, has been reported in a single level 4 study 28 of 12 patients to have remarkable efficacy in DS. Patients were treated for a mean of 11.4 years. Ten (83%) continued on fenfluramine at follow-up and seven (58%) were seizure-free for longer than a year. Fenfluramine combined with phentermine (Fen–Phen) was previously used as an anti-obesity treatment and was pulled off the market due to cardiac valvulopathy. However, in a Belgian study of DS, 28 mild heart valve thickening was seen in only two cases and was not progressive. A randomized placebo-controlled phase 3 study followed by a long-term open-label extension study of fenfluramine in DS is presently underway.


Despite much media attention, there are few reports in the literature that evaluate the efficacy of cannabinoids in DS. In a retrospective chart review 29 of 13 children with DS in a single center in Colorado who trialed various strains of oral cannabis extract, only 3 (23%) were responders. Somewhat more encouraging results were obtained in a multicenter open-label study of 25 patients 30 with DS who received >99% pure oil-based cannabidiol extract. After three months of treatment, the overall seizure frequency was reduced by 63% and 16% were seizure-free. A randomized placebo-controlled study of plant-based cannabidiol has just been completed, with early results showing it to be more efficacious than placebo. Overall, patients randomized to cannabidiol experienced a 39% reduction in monthly convulsive seizures compared to only 16% in the placebo group (p=0.01) (, although the results are not yet published.

Management of Status Epilepticus

All patients with Dravet syndrome are at risk of status epilepticus and should be provided with a home-rescue medication (diazepam, midazolam or lorazepam). In addition, each patient with DS should also have an individualized status epilepticus protocol, which can be carried out at their local emergency room. Based on a survey of 99 patients with DS from Japan, 26 efficacy for termination of ongoing status epilepticus was best with intravenous barbiturates (75-100%), modest with intravenous benzodiazepines (54.3-68.8%) and relatively low with intravenous lidocaine or phenytoin (15.4-21.4%).

Treatment of Other Co-Morbidities

Seizures in DS are clearly problematic, but they represent only one aspect of this disorder. While children are typically developmentally normal at seizure onset, nearly all develop intellectual disability over time. 2 Additionally, behavioural, sleep and psychological issues are problematic. 31 , 32 By adolescence, many develop a typical “crouch gait.” 33 , 34 Multidisciplinary team involvement—including neuropsychology, physical, occupational and speech therapy, and social work—is essential to maximize the quality of life and well-being for the patient with DS and their family.


Elaine Wirrell has the following disclosures: GW Pharma, site investigator (no financial compensation received, all monies going to the Mayo Clinic); Biocodex, other (research support), honoraria.


1. Wolff, M, Casse-Perrot, C, Dravet, C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl 2):45-48.
2. Ragona, F, Granata, T, Dalla Bernardina, B, Offredi, F, Darra, F, Battaglia, D, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 2011;52(2):386-392.
3. Nabbout, R, Chemaly, N, Chipaux, M, Barcia, G, Bouis, C, Dubouch, C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.
4. Thanh, TN, Chiron, C, Dellatolas, G, Rey, E, Pons, G, Vincent, J, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet syndrome) [in French]. Arch Pediatr. 2002;9(11):1120-1127.
5. Guerrini, R, Dravet, C, Genton, P, Belmonte, A, Kaminska, A, Dulac, O, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;38(5):508-512.
6. Chipaux, M, Villeneuve, N, Sabouraud, P, Desguerre, I, Boddaert, N, Depienne, C, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure. 2010;19(3):190-194.
7. Ceulemans, B. Overall management of patients with Dravet syndrome. Dev Med Child Neurol. 2011;53(Suppl 2):19-23.
8. Mueller, A, Boor, R, Coppola, G, Striano, P, Dahlin, M, von Stuelpnagel, C, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav. 2011;21(3):282-284.
9. Kassai, B, Chiron, C, Augier, S, Cucherat, M, Rey, E, Gueyffier, F, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343-348.
10. Coppola, G, Caliendo, G, Veggiotti, P, Romeo, A, Tortorella, G, De Marco, P, et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox–Gastaut syndrome: an Italian multicentric study. Epilepsy Res. 2002;51(1-2):147-153.
11. Nieto-Barrera, M, Candau, R, Nieto-Jimenez, M, Correa, A, del Portal, LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590-594.
12. Striano, P, Elefante, A, Coppola, A, Tortora, F, Zara, F, Minetti, C, et al. Dramatic response to levetiracetam in post-ischaemic Holmes’ tremor. J Neurol Neurosurg Psychiatry. 2007;78(4):438-439.
13. Centre for Evidence-Based Medicine. The Oxford 2011 Levels of Evidence. 2011. Available from:
14. Dressler, A, Trimmel-Schwahofer, P, Reithofer, E, Mühlebner, A, Gröppel, G, Reiter-Fink, E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome: comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81-89.
15. Inoue, Y, Ohtsuka, Y, STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90-97.
16. Fisher, JL. The effects of stiripentol on GABAA receptors. Epilepsia. 2011;52(Suppl 2):76-78.
17. Grosenbaugh, DK, Mott, DD. Stiripentol in refractory status epilepticus. Epilepsia. 2013;54(Suppl 6):103-105.
18. Fisher, JL. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190-197.
19. Chiron, C, Marchand, MC, Tran, A, Rey, E, d’Athis, P, Vincent, J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638-1642.
20. Inoue, Y, Ohtsuka, Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725-731.
21. Wirrell, EC, Laux, L, Franz, DN, Sullivan, J, Saneto, RP, Morse, RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54(9):1595-1604.
22. Kouga, T, Shimbo, H, Iai, M, Yamashita, S, Ishii, A, Ihara, Y, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015;37(2):243-249.
23. Kroll-Seger, J, Portilla, P, Dulac, O, Chiron, C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325-329.
24. Striano, P, Coppola, A, Pezzella, M, Ciampa, C, Specchio, N, Ragona, F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250-254.
25. Lotte, J, Haberlandt, E, Neubauer, B, Staudt, M, Kluger, GJ. Bromide in patients with SCN1A mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17-21.
26. Tanabe, T, Awaya, Y, Matsuishi, T, Iyoda, K, Nagai, T, Kurihara, M, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629-635.
27. Oguni, H, Hayashi, K, Oguni, M, Mukahira, A, Uehara, T, Fukuyama, Y, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35(6):1140-1145.
28. Ceulemans, B, Boel, M, Leyssens, K, Van Rossem, C, Neels, P, Jorens, PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131-1139.
29. Press, CA, Knupp, KG, Chapman, KE. Parental reporting of response to oral cannabis extract for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52.
30. Devinsky, O, Sullivan, J, Friedman, D, Thiele, E, Marsh, E, Laux, L, et al. Epidiolex (cannabidiol) in treatment-resistant epilepsy. Available from:
31. Dhamija, R, Erickson, MK, St Louis, EK, Wirrell, E, Kotagal, S. Sleep abnormalities in children with Dravet syndrome. Pediatr Neurol. 2014;50(5):474-478.
32. Skluzacek, JV, Parsy, O, Wical, B, Camfield, P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011;52(Suppl 2):95-101.
33. Rilstone, JJ, Coelho, FM, Minassian, BA, Andrade, DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53(8):1421-1428.
34. Rodda, JM, Scheffer, IE, McMahon, JM, Berkovic, SF, Graham, HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69(7):873-878.
35. Caraballo, RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52(Suppl 2):79-82.
36. Kang, HC, Kim, HD, Kim, DW. Short-term trial of a liquid ketogenic milk to infants with West syndrome. Brain Dev. 2006;28(1):67.
37. Nabbout, R, Copioli, C, Chipaux, M, Chemaly, N, Desguerre, I, Dulac, O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54-e57.
38. Laux, L, Blackford, R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;28(8):1041-1044.
39. Zamponi, N, Passamonti, C, Cappanera, S, Petrelli, C. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8-14.
40. Rossignol, E, Lortie, A, Thomas, T, Bouthiller, A, Scavarda, D, Mercier, C, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34-37.
41. Shahwan, A, Bailey, C, Maxiner, W, Harvey, AS. Vagus nerve stimulation for refractory epilepsy in children: more to VNS than seizure frequency reduction. Epilepsia. 2009;50(5):1220-1228.
42. Spatola, M, Jeannet, PY, Pollo, C, Wider, C, Labrum, R, Rossetti, AO. Effect of vagus nerve stimulation in an adult patient with Dravet syndrome: contribution to sudden unexpected death in epilepsy risk reduction? Eur Neurol. 2013;69(2):119-121.
43. Bremer, A, Lossius, MI, Nakken, KO. Dravet syndrome: considerable delay in making the diagnosis. Acta Neurol Scand. 2012;125(5):359-362.
44. Orosz, I, McCormick, D, Zamponi, N, Varadkar, S, Feucht, M, Parain, D, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia. 2014;55(10):1576-1584.